VAN-TELMISARTAN-HCTZ TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
07-11-2014
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
TELMISARTAN; HYDROCHLOROTHIAZIDE
Tillgänglig från:
VANC PHARMACEUTICALS INC
ATC-kod:
C09DA07
INN (International namn):
TELMISARTAN AND DIURETICS
Dos:
80MG; 12.5MG
Läkemedelsform:
TABLET
Sammansättning:
TELMISARTAN 80MG; HYDROCHLOROTHIAZIDE 12.5MG
Administreringssätt:
ORAL
Enheter i paketet:
28/30/100
Receptbelagda typ:
Prescription
Terapiområde:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0244783001; AHFS:
Bemyndigande status:
CANCELLED PRE MARKET
Tillstånd datum:
2019-07-31
Produktens egenskaper
_VAN-Telmisartan-HCTZ Product Monograph _
_ _
_ Page 1 of 53_
PRODUCT MONOGRAPH
Pr
VAN-TELMISARTAN-HCTZ
Telmisartan / Hydrochlorothiazide Tablets
80 mg/12.5 mg and 80 mg/25 mg
Manufacturer’s Standard
Angiotensin II AT
1
Receptor Blocker/Diuretic
MANUFACTURER AND DISTRIBUTOR:
Vanc Pharmaceuticals Inc.
Building 152, 11782 River Road
Richmond, BC V6X 1Z7
www.vancpharm.com
Date of Preparation:
November 7, 2014
Submission Control No: 179134
_VAN-Telmisartan-HCTZ Product Monograph _
_ _
_ Page 2 of 53_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................. 3
SUMMARY PRODUCT INFORMATION
.................................................................... 3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND PRECAUTIONS
...............................................................................
4
ADVERSE REACTIONS
...............................................................................................
11
DRUG INTERACTIONS
................................................................................................
21
DOSAGE AND ADMINISTRATION
...........................................................................
25
OVERDOSAGE
...............................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
........................................................ 28
STORAGE AND STABILITY
.......................................................................................
33
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................ 34
PART II: SCIENTIFIC INFORMATION
.......................................................................
35
PHARMACEUTICAL INFORMATION
.....................................................................
35
CLINICAL TRIALS
.......................
Läs hela dokumentet
